Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in the Netherlands: Influence and future implications

Journal of Comparative Effectiveness Research

Volumn 1, Issue 6, 2012, Pages 527-538

  Woerkom, Menno Van ^a   Piepenbrink, Hans ^b   Godman, Brian ^c,d,e   Metz, Joost De ^a   Campbell, Stephen ^f   Bennie, Marion ^g,h   Eimers, Marietta ^a   Gustafsson, Lars L ^c  

^a Dutch Institute for Rational Use of Medicine   (Netherlands)

^b Business Contact Centre and International Affairs   (Netherlands)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^h INFORMATION SERVICES DIVISION   (United Kingdom)

Author keywords

demand measures; drug utilization studies; generics; indicators; pharmaceuticals; proton pump inhibitors; reforms; statins; The Netherlands

Indexed keywords

ATORVASTATIN; CERIVASTATIN; ESOMEPRAZOLE; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROSUVASTATIN; SIMVASTATIN;

DATA BASE; DRUG COST; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HUMAN; NETHERLANDS; OBSERVATIONAL STUDY; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; REVIEW;

EID: 84873481509     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.12.52     Document Type: Review

References (59)

1. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24 (2010).
2. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8, 357-371 (2008).
3. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden-implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550 (2008). (Pubitemid 351871549)
4. Coma A, Zara C, Godman B et al. Policies to enhance the effciency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9, 569-581(2009).
5. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and effciency of statin and PPI prescribing in the UK; impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 73-85 (2010).
6. Garuoliene K, Godman B, Gulbinovič J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11, 341-347 (2011).
7. Abuelkhair M, Abdu S, Godman B et al. Imperative to consider multiple initiatives to maximise prescribing effciency from generic availability: case history from Abu Dhabi. Expert Rev. Pharmacoecon. Outcomes Res. 12, 115-124 (2012).
8. Godman B, Shrank W, Wettermark B et al. Use of generics-A critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010).
9. Godman B, Shrank W, AndersenM et al. Comparing policies to enhance prescribing effciency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722 (2010).
10. Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing effciency in Europe: fndings and future implications. Front. Pharmacol. 1(141), 1-16 (2011).
11. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems-A position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008).
12. Adamski J, Godman B, Oferska-Sujkowska G et al. Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers. BMC Health Serv. Res. 10, 153 (2010).
13. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking-An overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 137-147 (2009).
14. Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions-A necessary strategy among some European countries to enhance future prescribing effciency? Rev. Health Care 3, 5-16 (2012).
15. Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83 (2009).
16. Godman B, Wettermark B, Bishop I et al. European payer initiatives to reduce prescribing costs through use of generics. GABI 1, 22-27 (2012).
17. Petterson B, Hoffmann M, Wandell P, Levin LA. Utilisation and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104(1), 84-91 (2012).
18. Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94, 221-229 (2010).
19. Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-Assessment of prescribing patterns-A new approach for quality improvement of drug prescribing in primary care. Qual. Primary Care 17, 179-189 (2009).
20. Gustafsson LL, Wettermark B, Godman B et al. The 'Wise List'-A comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233 (2011).
21. Martikainen J, Saastamoinen L, Korhonen M et al. Impact of restricted reimbursement on the use of statins in Finland. Med. Care 48, 761-766 (2010).
22. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11, 121-129 (2011).
23. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing effciency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12, 125-130 (2012).
24. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9, 475-484 (2009).
25. Voncina L, Strizrep T. Croatia: 2009/2010 pharmaceutical pricing and reimbursement reform. Eurohealth 16, 20-22 (2011).
26. Vončina L, Strizrep T, Godman B et al. Infuence of demand side measures to enhance renin-Angiotensin prescribing effciency in Europe; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479 (2011).
27. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484 (2008). (Pubitemid 351197428)
28. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30-32 (2011).
29. Boonen LH, van der Geest SA, Schut FT, Varkevisser M. Pharmaceutical policy in The Netherlands: from price regulation towards managed competition. Adv. Health Econ. Health Serv. Res. 22, 53-76 (2010).
30. Schut F, Van De Ven W. Effects of purchaser competition in the Dutch health system: is the glass half full or half empty? Health Econ. Policy Law 6, 109-123 (2011).
31. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Offce of Fair Trading proposal for funding new drugs to beneft patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008).
32. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437-2445 (2005). (Pubitemid 41627921)
33. Weng TC, Kao Yang YH, Lin SJ, Tai SH. A systematic review and meta-Ana lysis on the therapeutic equivalence of statins. Clin. Phar. Ther. 35, 139-151 (2010).
34. Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326 (2009).
35. Roland M. Linking physicians' pay to the quality of care-A major experiment in the United Kingdom. NEJM 351, 1448-1454 (2004). (Pubitemid 39288172)
36. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. NEJM 355, 375-384 (2006). (Pubitemid 44127540)
37. Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in Defned Daily Dose in longitudinal drug consumption databases. Pharm. World Sci. 32, 125-129 (2010).
38. Eimers M, Nijpels M. Report-prescription behaviour monitor for general practioners 2011. Dutch institute for rational use of medicines postbus 3089, 3502 GB Utrecht.
39. Godman B, Abuelkhair M, Vitry A et al. Payers endorse generics to enhance prescribing effciency; impact and future implications, a case history approach. GABI 1(2), 10-20 (2012).
40. Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research fndings. BMJ 317, 465-468 (1998). (Pubitemid 28368041)
41. Barton S. Using clinical evidence. BMJ 322, 503-504 (2001). (Pubitemid 32230909)
42. Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947-2953 (2006). (Pubitemid 46021498)
43. Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-Acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 167, 950-955 (2007). (Pubitemid 46762758)
44. Leonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047-2056 (2007). (Pubitemid 47301504)
45. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch. Intern. Med. 70, 765-771 (2010).
46. Katz MH. Failing the acid test-benefts of proton pump inhibitors may not justify the risks for many users. Arch. Intern. Med. 170, 747-748 (2010).
47. Howell M, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium diffcile infection. Arch. Intern. Med. 170, 784-790 (2010).
48. Collins R, Armitage J, Parish S et al. MRC/HF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
49. Vooght GD, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in The Netherlands: a pharmacy database time trend study. Drugs Aging 27(7), 589-596 (2010).
50. Numans ME, De Wit NJ, Dirven JAM et al. NHG-standaard maagklachten (Tweede herziening). Huisarts Wet 46(12), 690-700 (2003). (Pubitemid 37409173)
51. van de Steeg-van Gompel C, Michel Wensing M, De Smet P. Implementation of a pharmacist-led intervention to enhance statin prescribing for secondary prevention in primary care: a cluster randomized trial. Eur. J. Prev. Cardiol. 19(2), 169-176 (2011).
52. Paes AH, Cornips PMJM. The emergence and development of pharmacotherapeutic meetings. Pharm. Weekbl. 122, 225-230 (1987).
53. Eimers M, de Groot J. FTO peiling 2005, kwaliteit van farmacotherapieoverleg in Nederland in beeld [PTAM audit 2005, quality of pharmacotherapeutical audit meetings in The Netherlands made visible]. DGV Nederlands instituut voor verantwoord medicijngebruik (DGV the Dutch Institute for the Proper Use of Medicine) (2006).
54. Trietsch J, van der Weijden T, Verstappen W et al. A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: study protocol. Implement. Sci. 4, 6 (2009).
55. Smulders Y, Burgers J, Scheltens T et al. Clinical practice guideline for cardiovascular risk management in The Netherlands. Netherlands J. Med. 66, 169-174 (2008). (Pubitemid 351593778)
56. Godman B, Wettermark B. Impact of reforms to enhance the quality and effciency of statin prescribing across 20 European countries. In: 9th Congress EACPT 2009. Webb D, Maxwell S (Eds). Medimond International Proceedings-Medimond s.t.l., Bologna, Italy, 65-69 (2009).
57. Godman B, Wettermark B. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. In: 9th Congress EACPT 2009. Webb D, Maxwell S (Eds). Medimond International Proceedings-Medimond s.t.l., Bologna, Italy, 71-75 (2009).
58. Markovic-Pekovic V, Ranko Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing effciency; infuence and future direction. Expert Rev. Pharmacoecon. Outcomes Res. (2012) (In press).
59. Godman B, Wettermark B, Bennie M et al. Enhancing prescribing effciency through increased utilisation of generics at low prices. (E)Hospital 13(3), 28-31 (2011).